To prevent neoplasia, cells of multicellular organisms activate cellular disposal programs such as apoptosis in response to deregulated oncogene expression, making the suppression of such programs an essential step for potentially neoplastic cells to become established as clinically relevant tumors. Since the mutation of ras proto-oncogenes, the most frequently mutated protooncogenes in human tumors, is very rare in some tumor types such as glioblastomas and gastric cancers, we hypothesized that mutated ras genes might activate a cell death program that cannot be overcome by these tumor types. Here we show that the expression of oncogenically mutated ras gene induces cellular degeneration accompanied by cytoplasmic vacuoles in human glioma and gastric cancer cell lines. Cells dying as a result of oncogenic Ras expression had relatively well-preserved nuclei that were negative for TUNEL staining. An immunocytochemical analysis demonstrated that the cytoplasmic vacuoles are derived mainly from lysosomes. This oncogenic Ras-induced cell death occurred in the absence of caspase activation, and was not inhibited by the overexpression of anti-apoptotic Bcl-2 protein. These observations suggested that oncogenic Ras-induced cell death is most consistent with a type of programmed cell death designated`type 2 physiological cell death' or autophagic degeneration', and that this cell death is regulated by a molecular mechanism distinct from that of apoptosis. Our ®ndings suggest a possible role for this non-apoptotic cell death in the prevention of neoplasia, and the activation of the non-apoptotic cell death program may become a potential cancer therapy complementing apoptosis-based therapies. In addition, the approach used in this study may be a valuable way to ®nd genetically-regulated cell suicide programs that cannot be overcome by particular tumor types.
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The ras proto-oncogenes encode small GTP-binding proteins that transduce, through association with multiple eector proteins, intracellular signals implicated in diverse biological processes including cellular proliferation and transformation (Barbacid, 1987; Hunter, 1997) . Mutations in ras alleles that constitutively activate Ras proteins occur in nearly 30% of all human tumors, making ras one of the most commonly activated proto-oncogenes (Bos, 1988 (Bos, , 1989 . Interestingly, the incidence of ras mutation varies greatly depending on the tissues or cell types from which cancer cells are derived: whereas the ras mutation rate is as high as 90% in pancreas cancers, ras mutation is extremely rare in several tumor types including glioblastomas (Bos, 1989) . However, at present, it remains unclear as to what is the critical factor that determines this cell type-dependent, uneven distribution of ras mutations in human cancers.
It has been shown that to transform primary cells, oncogenic ras expression alone is not sucient and requires other cooperating oncogenic alterations, for instance, overexpression of c-myc, cyclin D1, Cdc25A and -B, and loss of p53, p16, or IRF-1 (Land et al., 1983; Lovec et al., 1994; Tanaka et al., 1994; Galaktionov et al., 1995; Serrano et al., 1996) . As one of the possible explanations for this requirement, oncogenic ras expression is thought to activate cellular defense mechanisms such as apoptosis and senescence which need to be overcome by these cooperating oncogenic alterations for full malignant transformation (Tanaka et al., 1994; Serrano et al., 1997) . Thus, for cells harboring oncogenically mutated ras genes, whether oncogenic ras expression triggers cells' antiproliferative responses as a defense mechanism and whether the cells are capable of preventing the completion of such responses could be a major determinant of the cell fate, and may therefore be important factors determining the frequency of ras mutations in each tumor type. However, because the role of oncogenic ras-induced antiproliferative responses and its suppression in carcinogenesis has been analysed mainly using rodent ®broblasts (Tanaka et al., 1994; Serrano et al., 1997; Mayo et al., 1997) , the relevance of the ®ndings to human carcinogenesis remains unknown.
In this study, we therefore examined the consequence of oncogenic ras expression in human cancer cells. The results indicated that oncogenic ras expression induces cell death characterized by cytoplasmic vacuolization. Detailed morphological and molecular analyses suggested that this oncogenic rasinduced cell death is a genetically regulated cell death with a regulatory mechanism distinct from that of apoptosis.
Killing of human cancer cells by oncogenic ras gene expression
In contrast to many other tumor types, oncogenic mutation of ras is quite rare in glioblastomas (Bos, 1989) . As an explanation for this observation, we hypothesized that the expression of the oncogenic ras gene per se might have adverse eects on the survival and growth of human glioma cells. We therefore examined the eect of oncogenic H-Ras (Ras12V) expression in human glioma cells. As shown in Figure   1a , the transient transfection of the RasV12 expression vector into two malignant glioma cell lines, U251 and U343, produced degenerating cells with marked vacuolization in the cytoplasm. In contrast, the transfection of a control empty vector or a vector expressing dominant-negative H-Ras (RasN17) did not cause such cellular degeneration (not shown). We next asked whether this RasV12-induced cellular degeneration is speci®c to glioma cells. Since oncogenic ras mutation is also rare in gastric cancer (Bos, 1989) , we examined the eect of RasV12 expression in human gastric cancer cell lines MKN-1 and TMK-1. As with the glioma cells, RasV12 expression induced cellular degeneration accompanied by cytoplasmic vacuoles in the gastric cancer cell lines (Figure 1a) . However, interestingly, a transient RasV12 expression did not induce such cellular degeneration in T24, a human bladder cancer cell line known to harbor an oncogenic H-ras allele (Taparowsky et al., 1982) , although the expression level of RasV12 protein was comparable to that in the cell lines mentioned above (not shown). The ability of T24 to resist RasV12-induced cellular a b Figure 1 (a) The transient transfection of oncogenic ras(V12) gene induces cytoplasmic vacuolization and cellular degeneration in the glioblastoma cell lines U251, U343 and in the gastric cancer cell lines MKN-1, TMK-1. Cells were transfected with pcDNA3RasV12 plasmid vector expressing oncogenic H-ras (V12) gene under the control of a cytomegalovirus promoter by the lipofectin method as previously described (Kitanaka et al., 1995) , and were photographed under a phase-contrast microscope 2 days after transfection. Less (upper panel) and more (lower panel) severely aected cells are shown. Original magni®cation, 6100. (b) T24 bladder cancer cell line is resistant to oncogenic Ras-induced cell death. T24 and U251 cells were transfected with pcDNA3RasV12 plasmid vector (RasV12) or with control pcDNA3 vector (Vector) and were subjected to colony formation assay as previously described (Kitanaka et al., 1995) . Brie¯y, transfected cells (*2610 4 ) were seeded into 100 mm dishes 24 h after transfection, and drug selection by 1.2 mg/ml Geneticin was started after another 24 h. The numbers of colonies were counted 10 days after the transfection. Shown are the relative numbers of colonies compared to that of the vector control, which was set to 1 (n=2) degeneration was also demonstrated by the failure of RasV12 expression to inhibit colony formation of T24, which contrasted with the signi®cant suppression of colony formation of U251 by RasV12 (Figure 1b) .
To test the observations in transient transfection assays, we took advantage of a tetracycline-regulatable expression system (Adachi et al., 1996) and established stable U251 transfectants (U251TA-Ras) that inducibly express wild-type (wt) H-Ras, RasV12, or RasN17 upon the removal of tetracycline from the culture medium (Figure 2a ). Using these stable transfectants, we examined whether oncogenic Ras actually triggers cell death accompanied by cytoplasmic vacuolization. In control U251TA-GN cells (Vector), tetracycline withdrawal induced neither morphological changes nor any increase in the number of dead cells ( Figure  2b , and data not shown). In contrast, consistent with the observations in the transient transfection assays, the expression of RasV12 induced by tetracycline withdrawal did cause cell death accompanied by cytoplasmic vacuolization (Figure 2b , V12, and Figure  3a ). Though much less eciently compared to RasV12, wt-Ras expression also caused a slight increase in the dead cell fraction (Figure 2b , Wt). The expression of RasN17 did not induce cell death (Figure 2b , N17), but induced an elongated morphology and retarded growth compared with the vector control cells (not shown). These observations together indicated that oncogenic Ras has the ability to induce the cell death of human cancer cells, in a cell type-speci®c manner. The results also implied that oncogenic Ras-induced cell death does not necessarily require wt-p53, because U251, MKN-1, and TMK-1 cells express only mutated p53 (Matter et al., 1992; Asai et al., 1994) .
Characterization of cell death induced by oncogenic Ras expression
To characterize the cell death induced by oncogenic Ras, the time course of the morphological changes after the induction of RasV12 expression was followed under a phase-contrast microscope ( Figure 3a ). Morphological changes began within 24 h after tetracycline withdrawal, with cytoplasmic vacuoles appearing in some of the cells. Cytoplasmic vacuolization, which was clearly observed under a higher magni®cation (Figure 3a , right), eventually became severe and occurred in a large number of cells. By 5 days after the tetracycline withdrawal, a signi®cant proportion of the cells rounded up or fragmented into very small pieces (Figure 3a, left) .
Apparently, the morphological changes caused by RasV12 expression were distinct from those of U251 cells undergoing typical apoptosis, e.g., as a result of tumor necrosis factor alpha (TNF-a) treatment (see Figure 3b and e, Tc(+)+TNF). To determine whether the cell death we observed was apoptotic or nonapoptotic, an electron microscopic study was performed. As shown in Figure 3b , the cells dying as a result of RasV12 expression (Tc (7)) showed no signi®cant cell shrinkage or swelling compared with uninduced, normal cells (Tc(+)), but their cytoplasm was ®lled with vacuoles of multiple sizes. Importantly, the nucleus was intact in contrast to the marked cytoplasmic changes. Swelling of mitochondria was only occasionally observed and was mild in the dying cells. Under a higher magni®cation, some vacuoles found in the dying cells (Tc(7)) appeared to contain cytoplasmic components, suggesting that these vacuoles were derived from autolysosomes (not shown). These electron microscopic features were distinct from those of typical apoptosis or necrosis in that the nucleus was (V12), and U251TA-RasN17 (N17) cells established as described below were cultured for the indicated hours in the absence of tetracycline, and then cells were lysed in lysis buer (25 mM Tris-HCl [pH 7.6], 50 mM NaCl, 2% NP-40, 0.5% sodium deoxycholate, 0.2% SDS) supplemented with protease inhibitors. Cell lysates were separated by electrophoresis in a 15% SDS-polyacrylamide gel and immunoblotted with an antibody against H-Ras (C-20, Santa Cruz) essentially as previously described . (b) The U251TA cells examined in (a) were seeded and cultured in the absence of tetracycline, and the percentage of dead cells was determined by trypan blue dye exclusion at the indicated time points. To establish U251 cells that can inducibly express Ras proteins, U251 cells were ®rst transfected with pTAHyg vector expressing tTA and selected against Hygromycin B. U251 clones expressing tTA were identi®ed by Northern blot analysis and were further transfected with plasmid vectors (pT2GN) expressing ras genes under the control of the phCMV-1 promoter. After selection by Geneticin, U251 clones inducibly expressing Ras proteins were identi®ed by Northern blot and immunoblot analyses. Multiple clones were selected for each Ras, and we con®rmed that they show the same phenotypes described in the text when Ras expression was induced. Representative clones inducibly expressing wt-Ras, RasV12, and RasN17 were designated U251TA-wtRas, U251TA-RasV12, and U251TA-RasN17, respectively. A representative U251 clone produced by the transfection of control pT2GN vector and Geneticin selection (U251TA-GN) was used as a control. These U251TA clones were maintained in the presence of 200 units/ml Hygromycin B, 0.4 mg/ml Geneticin, and 2 mg/ml tetracycline unless otherwise indicated a b c Caspase-independent cell death induced by Ras S Chi et al well preserved and mitochondrial swelling was not predominant (Kerr et al., 1972) . Instead, the features seemed to coincide with those of`type 2 physiological cell death' (as opposed to`type 1 physiological cell death'=`apoptosis'), which is a type of programmed cell death characterized by the early appearance of lysosomally-derived, autophagic vacuoles and by delayed or minimal nuclear collapse (Schweichel and Merker, 1973; Clarke, 1990; Zakeri et al., 1995) . Type 2 cell death is also called`autophagic degeneration' because of the characteristic autophage vacuoles (Clarke, 1990; Zakeri et al., 1995) . Thus, the morphological features strongly suggested that RasV12-expressing cells were undergoing a type of Figure 3 Characterization of oncogenic Ras-induced cell death. (a) U251TA-RasV12 cells were seeded and cultured in the presence (Tc(+)) or absence (Tc (7)) of tetracycline. The cells were then photographed under a phase-contrast microscope (original magni®cation, 640) at the indicated time points after tetracycline withdrawal (left). Higher magni®cation views (6100) for day 3 are also shown (right). (b and c) Transmission electron microscopy analysis. U251TA-RasV12 cells treated as indicated in the ®gure were ®xed with 1% glutaraldehyde and post-®xed with 1% osmium tetroxide. After dehydration in graded ethanol, the cell pellets were embedded in epoxy resin and cut with an ultramicrotome. The sections were then stained with uranyl acetate and lead citrate, and observed with a transmission electron microscope. Tc(+), Tc(7); U251TA-RasV12 cells were cultured for 5 days (b) or 1.5 days (c) in the presence and absence of tetracycline, respectively. Tc(7)+zVAD; cells were cultured in the absence of tetracycline but in the presence of 100 mM zVAD-fmk (Kamiya Biomedical Company) for 5 days. Tc(+)+TNF; cells were treated with recombinant human TNF-a (Genzyme, 30 ng/ml) plus cycloheximide (Sigma, 20 mg/ml) in the presence of tetracycline for 24 h. Tc(+)+TNF+zVAD; cells were treated as in (Tc(+)+TNF), but in the presence of 100 mM zVAD-fmk). Scale bars, 5 mm (b); 2 mm (c). (d) Immunocytochemical analysis. U251TA-RasV12 cells were cultured on chamber slides in the absence of tetracycline for 4 days. After ®xation and permeabilization, cells were stained with primary antibodies against LAMP-1 (H4A3 hybridoma, supernatant diluted 1 : 100) (Chen et al., 1985) and M6PR (rabbit antiserum, diluted 1 : 100), and next with¯uorescein isothiocyanate (FITC)-conjugated anti-mouse and Texas Red-conjugated anti-rabbit secondary antibodies. The stained cells were visualized and photographed under a¯uorescence microscope. (e) Absence of DNA fragmentation in oncogenic Ras-induced cell death. U251TA-RasV12 cells were cultured in the presence (Tc(+)) or absence (Tc(7)) of tetracycline for 5 days, or were treated with TNF-a (30 ng/ml) plus cycloheximide (20 mg/ml) in the presence of tetracycline for 24 h (Tc(+)+TNF). Apoptotic DNA fragmentation was detected by using an in situ Apoptosis Detection Kit (Takara) and a Liquid DAB-Plus Substrate Kit (Zymed) according to the manufacturers' instructions. The nuclei were counterstained with methyl green e d
Caspase-independent cell death induced by Ras S Chi et al cell death distinct from apoptosis. However, it was also possible that the morphological changes observed in RasV12-induced cell death simply represented defective apoptosis in which nuclear collapse was selectively prevented as a result of defective execution machinery in these U251TA-RasV12 cells. To examine this possibility, we treated U251TA-RasV12 cells with TNF-a, which induces typical apoptosis in parental U251 cells, in the presence of tetracycline. In contrast to the cell death induced by RasV12 expression, the TNF-a-treated U251TA-RasV12 cells detached from the dish, shrank up, and showed typical apoptotic nuclear degradation on electron microscopic examination ( Figure 3b , Tc(+)+TNF). This result indicated that U251TA-RasV12 cells have functional eector machinery for the execution of apoptosis.
To further characterize the oncogenic Ras-induced cell death, we analysed its primary morphological changes, because the primary activation of the lysosomal apparatus is known as a characteristic feature of type 2 cell death (Schweichel and Merker, 1973) . As shown in Figure 3c , an electron microscopic analysis of the early stages of RasV12-induced cell death revealed that, preceding the overt cytoplasmic vacuolization, an increase of lysosomes containing electron-dense material was prominent in RasV12-expressing cells (Tc (7)), and some lysosomes showed early signs of vacuolization. In contrast, no increase of endocytotic vesicles abutting the plasma membrane was apparent, although Ras is known to be capable of stimulating pinocytosis (¯uid-phase endocytosis) (BarSagi and Feramisco, 1986) . We next examined the vacuoles by immunocytochemistry. The results indicated that lysosomal markers including lysosomeassociated membrane proteins-1, 2 (LAMPs-1, 2) and lysosomal glycoprotein 85 (LGP-85) co-localize with the vacuolar membrane (Figure 3d , and data not shown). Given the perinuclear localization of the vacuoles, it was also possible that the vacuoles were abnormally accumulated late endosomes (Feng et al., 1995) . However, mannose 6-phosphate receptor (M6PR), a marker for late endosomes, did not colocalize with the membrane for most of the vacuoles (Figure 3d ). These results de®nitively indicated that the vacuoles were derived predominantly from lysosomes and that the contribution of endosomes was small. All of these ®ndings were quite consistent with type 2 physiological cell death (Schweichel and Merker, 1973; Clarke, 1990; Zakeri et al., 1995) , although intense endocytosis may occasionally accompany type 2 cell death (Clarke, 1990) . We also tested a speci®c inhibitor of autophagy, 3-methyladenine (Seglen and Gordon, 1982), on RasV12-induced cytoplasmic vacuolization. The addition of 3-methyladenine to the culture medium inhibited RasV12-induced cytoplasmic vacuolization in a dose-dependent manner (data not shown), which suggested that an autophagic process (autophagic sequestration) is indeed involved in the formation of cytoplasmic vacuoles (Hùyvik et al., 1991) .
As shown in Figure 3b , the electron microscopic analysis demonstrated that the nuclear morphology is preserved during the RasV12-induced cell death without remarkable changes until the ultimate cell disintegration. We therefore examined with a terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) analysis whether chromosomal DNA remained intact during the RasV12-induced non-apoptotic cell death. The nuclei of the dying cells treated with TNF-a were strongly positive for TUNEL, demonstrating the apoptotic nature of TNF-a-induced cell death (Figure 3e , Tc(+)+TNF). However, in sharp contrast, the nuclei of the cells dying as a result of RasV12 expression were negative for TUNEL, indicating the absence of chromosomal DNA fragmentation during RasV12-induced cell death (Figure 3e , Tc (7)). Thus, oncogenic Ras-induced cell death involves neither morphological nor biochemical nuclear changes indicative of apoptosis.
Absence of caspase activation during oncogenic Ras-induced cell death
We next examined whether oncogenic Ras-induced cell death shares a common regulatory mechanism with apoptotic cell death. Since caspases have been shown to play a central role not only in apoptotic cell death but even in some forms of necrosis (Kumar and Lavin, 1996; Shimizu et al., 1996) , we examined whether the activation of caspases is also involved in oncogenic Ras-induced cell death. We ®rst measured caspase-1-like and caspase-3-like protease activities cleaving the YVAD and DEVD sequences, respectively (Enari et al., 1996) , in cell lysates prepared from U251TA-RasV12 cells dying as a result of RasV12 expression. As shown in Figure 4a , neither caspase-1-like nor caspase-3-like protease activity was induced during RasV12-induced cell death. In contrast, caspase-3-like protease activity was signi®cantly induced when U251TA-RasV12 cells were treated with TNF-a in the presence of tetracycline, which assured that apoptotic caspases were functional in U251TA-RasV12 cells (Figure 4b ). We further examined caspase activation by immunoblot analysis ( Figure  4c) . In TNF-a-treated U251TA-RasV12 cells, the processing of caspase-3 occurred accompanied by the processing of poly(ADP-ribose) polymerase (PARP) into a speci®c 85 kDa fragment (Figure 4c, lane 3) . Caspase-2 was not processed during TNF-a-induced apoptosis, and caspase-1 was not detectable either in TNF-a-treated or untreated U251TA-RasV12 cells (data not shown). In contrast, neither caspase-3 nor PARP was processed during RasV12-induced cell death ( Figure 4c, lane 2) . Since the activation of caspase-3-like proteases is thought to be the pivotal step of the caspase activation cascade during the execution of apoptosis (Faleiro et al., 1997) , these results suggested that caspase activation is not involved in RasV12-induced cell death. To further test this idea, we examined the eects of the broad-spectrum caspase inhibitors, zVAD-fmk and Z-Asp-CH 2 -DCB, on RasV12-induced cell death. As expected, these caspase inhibitors eectively suppressed the TNF-a-induced activation of caspase-3-like proteases (Figure 4b , and data not shown), the processing of caspase-3 and PARP (Figure 4c , lane 4, and data not shown), and apoptotic cell death (Figure 4d ) in U251TA-RasV12 cells. However, under the same conditions, these inhibitors failed to suppress RasV12-induced cell death (Figure 4e ). Consistent with these results, zVAD-fmk also failed to inhibit RasV12-induced morphological changes including cytoplasmic vacuoli- Lysates prepared from U251TA-RasV12 cells as in Figure 2a were separated by SDS-polyacrylamide gel electrophoresis and immunoblotted with antibodies against caspase-2, caspase-3 (Transduction Laboratories), and PARP (C-20, Enzyme System Products) as previously described . Lanes: 1, cultured in the presence of tetracycline for 5 days; 2, cultured in the absence of tetracycline for 5 days; 3, treated with TNF-a (30 ng/ml) plus cycloheximide (20 mg/ml) in the presence of tetracycline for 24 h; 4, same as 3, but in the presence of 100 mM zVAD-fmk. The unprocessed form (procaspase) is shown for caspases-2 and 3. (d and e) Broad-spectrum caspase inhibitors inhibit TNF-a-induced apoptosis but not oncogenic Ras-induced cell death. U251TA-RasV12 cells were either treated with TNF-a (30 ng/ml) plus cycloheximide (20 mg/ml) in the presence of tetracycline for 24 h (d) or cultured in medium lacking tetracycline for 5 days (e), in the presence of the indicated concentrations of zVAD-fmk (zVAD) or Z-Asp-CH 2 -DCB (Z-Asp). The percentage of dead cells was then determined by trypan blue dye exclusion (n=2) zation (Figure 3b , Tc(7)+zVAD) while eectively inhibiting the morphological changes associated with TNF-a-induced apoptosis (Figure 3b , Tc(+)+ TNF+zVAD). Together, these results suggest that caspase activation is not involved in oncogenic Rasinduced cell death.
Lack of inhibitory eect of anti-apoptotic Bcl-2 protein on oncogenic Ras-induced cell death
In addition to caspases, we also examined the possible role of the Bcl-2 protein family, another group of basic regulators of cell death, in oncogenic Ras-induced cell death. An immunoblot analysis demonstrated that the expression levels of Bcl-2 family members such as Bcl-2, Bcl-x L , Bax, and Bak remained unaected during RasV12-induced cell death (data not shown). Colony formation assays showed that the U251Bcl-2 cells, which overexpress exogenously introduced human Bcl-2 protein ( Figure 5a ) and have thereby acquired signi®cant resistance against TNF-a treatment ( Figure  5b ), were not apparently resistant against RasV12-induced cell death ( Figure 5c ). Thus, these results suggest that the Bcl-2 family may not play a major role in the regulation of oncogenic Ras-induced cell death, as it does in apoptosis.
Non-apoptotic cell death induced by oncogenic Ras
In the present study, we demonstrated that oncogenic Ras activates a cell suicide program in human cancer cells. Oncogenic Ras-induced cell death occurred in the absence of the caspase activation essential for apoptosis execution (Kumar and Lavin, 1996) . This cell death did not require wt-p53 activity and was not inhibitable by anti-apoptotic Bcl-2 protein. In addition, oncogenic Ras-induced cell death was dependent on the activity of phosphatidylinositol-3-OH kinase (PI(3)K), a physiological downstream eector of Ras (Rodriguez-Viciana et al., 1994) , that is thought to mediate survival signals inhibiting apoptotic cell death (Franke et al., 1997) , since this cell death was inhibited by speci®c inhibitors of PI(3)K (manuscript in preparation). These results together suggested that oncogenic Ras-induced cell death is regulated by a molecular mechanism distinct from that of apoptosis.
In agreement with this, morphological and immunocytochemical ®ndings suggested that this cell death is most consistent with type 2 physiological cell death, a type of programmed cell death that has been distinguished from apoptosis (type 1 cell death) mainly on a morphological basis (Schweichel and Merker, 1973; Clarke, 1990; Zakeri et al., 1995) . Similar to apoptosis, this type 2 cell death has been shown to occur in various tissues of both invertebrates and vertebrates, particularly where tissue areas or anlagen of organs are removed in toto during embryonic development (Schweichel and Merker, 1973; Clarke, 1990; Zakeri et al., 1995) . The involvement of this type of cell death has been demonstrated in the aected neurons in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease (Cataldo et al., 1994 (Cataldo et al., , 1995 Anglade et al., 1997) , suggesting its important role in human pathology. However, despite such potential physiological and pathological significance, the regulatory mechanism of type 2 cell death a b c Figure 5 Lack of inhibitory eect of anti-apoptotic Bcl-2 protein on oncogenic Ras-induced cell death. (a) Expression level of Bcl-2 protein in U251 cells and U251Bcl-2 cells overexpressing transfected Bcl-2. Cell lysates prepared as in Figure 2a were separated by SDS-polyacrylamide gel electrophoresis and immunoblotted with an anti-Bcl-2 antibody (N-19, Santa Cruz), as previously described . (b) Bcl-2 overexpression protects U251 cells from TNF-a-induced apoptosis. U251 cells and U251Bcl-2 cells were treated with TNF-a (30 ng/ml) plus cycloheximide (20 mg/ml). As a control, both cells were cultured in the presence of 20 mg/ ml cycloheximide without TNF-a. After 24 h, cell viability was determined by trypan blue dye exclusion. The graph shows the viability of TNF-a-treated U251 and U251Bcl-2 cells relative to control (n=2). (c) U251 and U251Bcl-2 cells are equally sensitive to oncogenic Ras-induced cell death. U251 and U251Bcl-2 cells were transfected with pcDNA3 plasmid vector expressing RasV12 or with control pcDNA3 vector and were subjected to colony formation assay as in Figure 1b . The relative number of colonies as compared with vector control (=1, not shown in this graph) is presented (n=4) has remained totally enigmatic in contrast to apoptosis. In this regard, oncogenic Ras-induced cell death serves as a valuable model system to understand the regulatory mechanisms involved in non-apoptotic types of programmed cell death such as type 2 death and hence will contribute to the comprehensive understanding of programmed cell death in general.
Implication of oncogenic Ras-induced non-apoptotic cell death in human carcinogenesis and cancer therapy
Previous studies using rodent ®broblasts suggested that apoptosis and senescence induced by oncogenic ras expression play an important role in the prevention of ras-induced cellular transformation (Tanaka et al., 1994; Serrano et al., 1997; Mayo et al., 1997) . However, in human cancer cells derived from gliomas and gastric cancers, the expression of oncogenic H-ras induced non-apoptotic cell death instead of apoptosis and senescence, as shown in this study. According to previous reports surveying the incidence of ras mutations in human cancers (Bos, 1988 (Bos, , 1989 , H-ras mutation is much less frequent than K-and N-ras mutation despite the no less strong transforming activity of oncogenic H-ras compared to oncogenic K-and N-ras (Maher et al., 1995) , and has not been detected in glioblastomas and gastric cancers. Because our preliminary observation indicates that oncogenic K-and N-ras (V12) show reduced ability to induce non-apoptotic cell death compared to oncogenic H-ras when similarly expressed in glioma cells in transient transfection assays (unpublished observation), these ®ndings together suggest that non-apoptotic cell death, as well as apoptosis and senescence, may also contribute to the elimination of potentially neoplastic cells in human, and the strong pro-death activity of oncogenic H-ras may be a possible explanation for the relatively low incidence of H-ras mutation in human cancer, represented by its absence in glioblastomas and gastric cancers. Our results also imply that cells which have acquired oncogenic mutation of ras gene during malignant progression need to suppress the activation of the cell death program in order to survive and grow, as demonstrated by the resistance of T24 human bladder cancer cells against oncogenic H-Ras-induced cell death. Thus, the ability of oncogenic Ras to activate the non-apoptotic cell death program and the ability of the cells to overcome non-apoptotic cell death may be one of the critical determinants of the cell fate during human carcinogenesis involving ras mutation. Cancer cells are known to acquire resistance against apoptosis through, for instance, p53 inactivation and Bcl-2 overexpression during multistep carcinogenesis, and this increased resistance against apoptosis becomes a great obstacle to anticancer treatments such as ionizing radiation and chemotherapeutic agents which depend on their ability to induce apoptosis for killing (Fisher, 1994) . In this respect, the activation of a nonapoptotic cell death program may be a promising therapeutic approach to human cancer, because oncogenic Ras-induced cell death was neither dependent on wt-p53 nor inhibitable by Bcl-2 overexpression. At present, expression of RasV12 is the only known way to eciently activate the non-apoptotic cell death program. However, when applications to gene therapy are considered, the potential oncogenicity of RasV12 toward the surrounding non-neoplastic cells may become a major problem. Since we have found that a transformation-defective mutant of RasV12 which selectively activates the downstream eectors of Ras (Rodriguez-Viciana et al., 1997), can induce cell death no less eciently than RasV12 (manuscript in preparation), use of this mutant would be an option to avoid such a risk. Undoubtedly, further elucidation of the molecular mechanisms involved in oncogenic Ras-induced non-apoptotic cell death will lead to the identi®cation of alternative methods to eciently trigger this genetically regulated, non-apoptotic cell death without undesired eects. Since the mechanisms underlying the resistance to apoptotic cell death and non-apoptotic cell death are likely to be distinct, these methods will serve as a basis for developing potential therapies against human cancer that complement the currently used apoptosis-based therapies.
Finally, we focused in this study on a genetic alteration (ras mutation) that is unexpectedly infrequent in particular tumor types (glioblastomas and gastric cancers), and by so doing found that oncogenic Ras eectively activates a non-apoptotic suicide program in those cell types. The focus of oncogene research is often directed toward how oncogene expression contributes to tumorigenesis, but our approach was quite unique in that we focused on how oncogene expression contributes to the suppression of tumorigenesis through the activation of cell suicide programs. Such an approach may be useful, as we have demonstrated, for the identi®cation of genetically regulated cell suicide programs that are eective in eliminating neoplastic cells, and may thus contribute to designing eective therapies against human cancer.
